Not What the Obesity Doctor Ordered
Arena Pharmaceuticals announces dismal fourth-quarter sales. Can Aetna help VIVUS turn things around?
A Short-Lived FDA Approval Pop
Vanda Pharmaceuticals gained FDA approval for Hetlioz, but investors appear worried about how the drug will sell. Arena Pharmaceuticals and VIVUS are good examples of other biotechs that haven't lived up to their expectations.